Cancer statistics: The United States vs. worldwide.

Abstract

e23276 Background: Cancer is now a pandemic worldwide. Although the mortality from cancer is downtrending due to the advent of newer treatment modalities, the global burden of cancer is exponentially increasing due to early detection.Understanding the current cancer demographics can aid in developing strategies to curb the morbidity and mortality from these malignancies. Methods: The data was obtained using 2 databases: GLOBOCAN for global trends, & Surveillance, Epidemiology and End Result database Research Plus Data, 17 Registries, Nov 2022 Sub (2000-2020) for the data in the United States (US). We further stratified SEER data based on incidence, gender & median months of survival (mOS), using the Log-rank test (GraphPad Prism). Results: As per the latest GLOBOCAN analysis, 18,094,716 new cancers (51.63% males,48.36% females) & 9,894,402 deaths (55.49% males, 44.51% females) from cancer occurred, worldwide. The 5 most commonly diagnosed cancers globally were, breast (12.5%), lung (12.2%), colorectal cancer (CRC) (10.7%), prostate (7.8%), & stomach (6%). However, the 5 most common cancers causing mortality globally, were lung (18.2%), CRC (9.5%), liver (8.4%) stomach (7.8%), & breast (6.9%). Whereas, in the US, 2,281,658 new cancers (males 53.75%, females 46.24%) were detected in 2020, & 612,390 deaths (males 52.58%, females 47.41%) occurred from it. The 5 most commonly diagnosed cancers were breast (11.1%), lung (10%), prostate (9.2%), CRC (6.8%), & melanoma (4.2%). Cancer-related mortality was attributed to lung (22.6%), CRC (8.9%), pancreas (7.8%), breast (7%), & prostate (5.3%). SEER data analysis for cancer mortality in the US is listed below in Table 1. Conclusions: Analysis of 2 large databases show that the most common cancers around the world, including the US, are breast, lung, colon & prostate cancers. Breast cancer has the highest incidence, but lung cancer has the highest mortality worldwide. In the US, Whites are more affected & except breast cancer, males have a greater predeliction for the common cancers. mOS was greater for females over all. This study emphasizes the need for further analysis to introspect if modalities such as next generation sequencing-directed immunotherapy would prove beneficial in increasing overall survival. [Table: see text]